INVITED SPEAKER

STEPHEN ROBERTS, MD, PhD

Modeling Neuroblastoma using Human Pluripotent Stem Cells

WHEN

December 14, 2016
13:00-13:50

WHERE

AUD 1-1K3, UZ GENT

Hosted by
Prof. Dr. Frank Speleman

Biography

Dr. Roberts is a pediatric oncologist with the neuroblastoma program at Memorial Sloan Kettering Cancer Center. Both his clinical practice and research are devoted to the treatment of neuroblastoma. His primary research interest is in understanding the developmental biology of neuroblastoma so that we can identify the causes of its extreme clinical heterogeneity. By identifying and understanding these differences, we will be able to develop new therapeutic approaches that promise to be both more effective and less toxic than our current therapies. Additionally, Dr. Roberts currently serves as acting Co-Director for Pediatric Developmental Therapeutics at MSKCC, where he is actively involved in early phase I and II pediatric clinical trials.

Key papers

1. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma. Kushner BH, Cheung NV, Modak S, Becher OJ, Basu EM, Roberts SS, Kramer K, Dunkel IJ. Int J Cancer. 2017.
2. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, Roberts SS, Basu EM, Yataghene K, Cheung NK. Oncotarget. 2016.
3. Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era. Kushner BH, Modak S, Kramer K, LaQuaglia MP, Yataghene K, Basu EM, Roberts SS, Cheung NK. Cancer. 2014.

CRIG CENTER MEDICAL GENETICS GHENT GHENT UNIVERSITY